Cargando…
MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-X(L) expression
There have been few advances in the treatment of small-cell lung cancer (SCLC) because of the lack of targets. MCL1, a member of the anti-apoptotic BCL-2 family, may be a treatment target in several cancers, including SCLC. However, whether the expression profile of the anti-apoptotic BCL-2 family a...
Autores principales: | Yasuda, Yuto, Ozasa, Hiroaki, Kim, Young Hak, Yamazoe, Masatoshi, Ajimizu, Hitomi, Yamamoto Funazo, Tomoko, Nomizo, Takashi, Tsuji, Takahiro, Yoshida, Hironori, Sakamori, Yuichi, Nakajima, Naoki, Menju, Toshi, Yoshizawa, Akihiko, Date, Hiroshi, Hirai, Toyohiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7063049/ https://www.ncbi.nlm.nih.gov/pubmed/32152266 http://dx.doi.org/10.1038/s41419-020-2379-2 |
Ejemplares similares
-
YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation
por: Tsuji, Takahiro, et al.
Publicado: (2020) -
Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer
por: Tsuji, Takahiro, et al.
Publicado: (2017) -
Sarcomatoid malignant pleural mesothelioma treated with nivolumab: A case series
por: Hashimoto, Kentaro, et al.
Publicado: (2022) -
CD47 polymorphism for predicting nivolumab benefit in patients with advanced non‑small‑cell lung cancer
por: Ogimoto, Tatsuya, et al.
Publicado: (2023) -
Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab
por: Funazo, Tomoko Yamamoto, et al.
Publicado: (2019)